Device Trial Radar · NCT07938060
Study of the BioRISE Biolimus Drug-Coated Balloon Versus the SELUTION SLR Sirolimus-Coated Balloon in De Novo Coronary Lesions, With a Single-Arm In-Stent Restenosis Cohort (SUNRISE)
Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
443
Planned (sponsor's estimate)
Start
Mar 1, 2027
Primary completion
Jan 31, 2029
Study completion Mar 31, 2031
Sponsor
- Lead sponsor
- Biosensors Europe SANot on our public-company list
- Sponsor type
- Industry
- First posted
- Nov 16, 2026
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Coronary heart disease causes narrowing of the heart (coronary) arteries (arteries are blood vessels, which supply oxygen-rich blood to the heart muscle). Your heart specialist will have explained to you that they suspect that you have a narrowing in one or more of your heart arteries. This narrowing may be causing you to have chest pains or evidence of reduced blood supply to your heart muscle. One commonly used treatment for this problem is to stretch the narrowing with a balloon and then insert a small mesh-like device called a stent, which will hold the artery open, improving the blood flow to your heart, and thereby help with your symptoms. An alternative treatment is to open the narrowing with a balloon that is coated with an anti-inflammatory drug (so called drug-coated balloon) as treatment instead of a stent. Drug-coated balloons are used to reduce the risk of re-narrowing of your coronary arteries without leaving an implant (like a stent) behind. A stent (which is a foreign object that does not belong in the body) can cause vessel inflammation and it bears the risk of blockage within the stent (in-stent restenosis or ISR). Drug-coated balloons leave no implant behind but target the narrowing in your vessel wall with the delivery of an anti-inflammatory agent to the vessel wall, allowing the blood vessel to heal. Biosensors has developed a balloon coated with a drug called Biolimus A9™ which suppresses inflammation in the artery where the narrowing has occurred. We refer to this balloon coated with Biolimus A9™ as BA9-DCB (Biolimus A9™ drug-coated balloon) also known as BioRISE. This device is not commercially available and will be tested in this study for the first time in humans. However, several coronary stents made by Biosensors are already on the market that contain the Biolimus A9™ drug. It has been proven to be safe and effective in preventing re-narrowing of the artery where the stent is placed. In this study, two types of drug-coated balloons (DCBs) will be used; the BioRISE (test group; group 1) and SELUTION SLR, a balloon that is coated with sirolimus (control group; group 2). The SELUTION SLR balloon is commercially available in Europe. The study has the following design: • Patients will be treated according to standard hospital procedures using the study device. The study has the following design: * Patients will be treated according to standard hospital procedures using the study device. * There will be two different types of patients included in this study. * 400 patients with a narrowing in a heart artery that has never been treated before (referred to as de novo disease), of whom 200 will be treated with the BioRISE balloon and 200 with the SELUTION SLR balloon. The allocation to the two possible treatments is random as it must be in a study like this. Of these 400 patients, 15 in each treatment arm, will have the inside of the artery imaged during the procedure using a well-established technique called Optical Coherence Tomography (OCT) and Quantitative Flow Ratio (QFR) * 43 patients with a narrowing inside a stent that was implanted in the past (referred to as in-stent restenosis). In these patients, only the BioRISE balloon will be used. * Your doctor will explain to which category applies to you. * There will be up to 25 hospitals taking part in the study in the UK, and in up to 5 European countries * Patients will be taking part in the study for up to 3 years, and during this time their health status will be assessed by telephone or hospital visit at 1month, 9 month, 12 months, 24 months and 36 months. * There will be a check up angiography to assess the primary end point at 9 months for all participants.
Conditions
- Angina (Stable)
- Unstable Angina (UA)
- NSTEMI
Interventions
Biolimus A9 Drug Coated BalloonDevice
Interventions in BioRISE arm aim to improve coronary luminal diameter for the treatment of de novo lesions well as lesions resulting from In-Stent Restenosis
SELUTION SLRDevice
The comparator applies to the de novo randomised cohort only; the single-arm ISR cohort has no comparator.
Primary outcomes
What the sponsor says the trial is designed to measure.
- In-segment Late Lumen Loss (LLL) at 9 monthsTime frame: 9 months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Royal Bournemouth Hospital
Bournemouth, United Kingdom
University of Bristol
Bristol, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.